Hengrui Pharmaceutical (600276.SH): HRS9531 injection obtained drug clinical trial approval notice

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS9531 injection, which will conduct clinical trials in the near future.

HRS9531 injection is a novel dual agonist targeting gastric suppressive peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) with HRS9531 as the main active ingredient. Its marketing application for long-term adult weight management was accepted by the State Drug Administration in September 2025.